Curis, Inc. (NASDAQ:CRIS – Get Rating) was the target of a large drop in short interest in May. As of May 31st, there was short interest totalling 1,880,000 shares, a drop of 5.1% from the May 15th total of 1,980,000 shares. Based on an average daily trading volume, of 374,300 shares, the days-to-cover ratio is […]
Curis (NASDAQ:CRIS – Get Rating) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Monday. Curis Trading Down 3.5 % Shares of NASDAQ:CRIS opened at $0.79 on Monday. Curis has a 12-month low of $0.47 and a 12-month high of $1.77. The company has a market […]
Curis (NASDAQ:CRIS – Get Rating) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01), RTT News reports. The company had revenue of $2.30 million for the quarter, compared to analysts’ expectations of $2.49 million. Curis had a negative […]
/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.
/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.